Tyme Technologies Inc
NASDAQ:TYME
Tyme Technologies Inc
Total Equity
Tyme Technologies Inc
Total Equity Peer Comparison
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tyme Technologies Inc
NASDAQ:TYME
|
Total Equity
$74.1m
|
CAGR 3-Years
84%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$8B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$17.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$5B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$27B
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
See Also
What is Tyme Technologies Inc's Total Equity?
Total Equity
74.1m
USD
Based on the financial report for Jun 30, 2022, Tyme Technologies Inc's Total Equity amounts to 74.1m USD.
What is Tyme Technologies Inc's Total Equity growth rate?
Total Equity CAGR 5Y
54%
Over the last year, the Total Equity growth was -23%. The average annual Total Equity growth rates for Tyme Technologies Inc have been 84% over the past three years , 54% over the past five years .